
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aspire Reports Positive Trial Of Sublingual Aspirin For Suspected Heart Attack
Details : Acetylsalicylic acid works by irreversibly inactivating COX-1, thereby blocking the generation of thromboxane A2, derives a potential antiplatelet effect, in patients having heart attack.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 18, 2025
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aspire Biopharma Doses First Patient in Phase 1 Trial for Fast-Acting Oral Aspirin
Details : The first patient has been dosed in Aspire's Phase I to evaluate its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
